Veracyte (VCYT) News Today → WATCH: The Truth About Inflation (From Birch Gold) (Ad) Free VCYT Stock Alerts $23.55 +0.53 (+2.30%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 5:03 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Bought by Russell Investments Group Ltd.Russell Investments Group Ltd. boosted its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 102.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 84,808 shares of the biotechnology compaMay 15 at 1:54 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 14 at 6:40 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Short Interest UpdateMay 12, 2024 | marketbeat.comEssex Investment Management Co. LLC Has $3.11 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)Essex Investment Management Co. LLC lessened its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 35.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,934 shares of the biotechnology company's stock after selling 62,815 sMay 10, 2024 | markets.businessinsider.comVeracyte’s Robust Performance and Growth Potential Reinforce Buy RatingMay 10, 2024 | markets.businessinsider.comVeracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy RatingMay 10, 2024 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Given New $27.00 Price Target at Needham & Company LLCMay 9, 2024 | finance.yahoo.comIs Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?May 8, 2024 | markets.businessinsider.comMaintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward ProfitabilityMay 8, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comNeedham & Company LLC Cuts Veracyte (NASDAQ:VCYT) Price Target to $27.00Needham & Company LLC cut their price target on Veracyte from $33.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday.May 8, 2024 | marketbeat.comVeracyte (NASDAQ:VCYT) Posts Earnings ResultsVeracyte (NASDAQ:VCYT - Get Free Report) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.17. Veracyte had a negative return on equity of 2.02% and a negative net margin of 20.61%. The company had revenue of $96.84 million during the quarter, compared to analysts' expectations of $93.35 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. The company's revenue for the quarter was up 17.5% compared to the same quarter last year.May 8, 2024 | finance.yahoo.comVeracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ...May 7, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test PerformanceMay 7, 2024 | seekingalpha.comVeracyte, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | businesswire.comVeracyte Announces First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comHere's what to expect from Veracyte's earningsMay 6, 2024 | businesswire.com14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingMay 5, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Fisher Asset Management LLCFisher Asset Management LLC cut its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 13.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 874,471 shares of the biotechnology company's stock after selling 130,958 shareMay 4, 2024 | marketbeat.comVestmark Advisory Solutions Inc. Acquires New Holdings in Veracyte, Inc. (NASDAQ:VCYT)Vestmark Advisory Solutions Inc. acquired a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 176,315 shares of tApril 27, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by New York State Common Retirement FundNew York State Common Retirement Fund trimmed its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 837,467 shares of the biotechnology company's stoApril 26, 2024 | bizjournals.comDiagnostics pioneer Bonnie Anderson launches PinkDx to focus on women's healthApril 25, 2024 | marketbeat.comSemanteon Capital Management LP Makes New $1.24 Million Investment in Veracyte, Inc. (NASDAQ:VCYT)Semanteon Capital Management LP acquired a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,989 shares of the biotechnology company'April 22, 2024 | businesswire.comVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024April 22, 2024 | finance.yahoo.comNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 22, 2024 | businesswire.comNew Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 18, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Cuts Position in Veracyte, Inc. (NASDAQ:VCYT)Sumitomo Mitsui Trust Holdings Inc. cut its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 2.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,104,676 shares of the biotechnology company's stock after selling 68,900 shares durinApril 17, 2024 | finance.yahoo.comVeracyte, Inc. (VCYT)April 16, 2024 | businesswire.comVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024April 15, 2024 | marketbeat.comVeracyte (NASDAQ:VCYT) Sets New 1-Year Low on Analyst DowngradeVeracyte (NASDAQ:VCYT) Hits New 52-Week Low After Analyst DowngradeApril 15, 2024 | marketbeat.comThe Goldman Sachs Group Cuts Veracyte (NASDAQ:VCYT) Price Target to $28.00The Goldman Sachs Group decreased their price target on shares of Veracyte from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Monday.April 14, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 251,865 Shares of Veracyte, Inc. (NASDAQ:VCYT)Mirae Asset Global Investments Co. Ltd. lowered its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 47.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 280,062 shares of the bApril 13, 2024 | marketbeat.comShort Interest in Veracyte, Inc. (NASDAQ:VCYT) Increases By 32.8%Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 3,640,000 shares, an increase of 32.8% from the March 15th total of 2,740,000 shares. Based on an average daily trading volume, of 633,600 shares, the short-interest ratio is currently 5.7 days.April 9, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Stock Holdings Reduced by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 80.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,943 shares of the biotechnologyApril 3, 2024 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Director Karin Eastham Sells 10,000 SharesApril 2, 2024 | finance.yahoo.comWhat Makes Veracyte (VCYT) a Lucrative Investment?March 28, 2024 | marketbeat.comARK Investment Management LLC Acquires 62,011 Shares of Veracyte, Inc. (NASDAQ:VCYT)ARK Investment Management LLC raised its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,655,603 shares of the biotechnology company's stock after buying anMarch 20, 2024 | marketbeat.comAEGON ASSET MANAGEMENT UK Plc Makes New $9.59 Million Investment in Veracyte, Inc. (NASDAQ:VCYT)AEGON ASSET MANAGEMENT UK Plc bought a new position in Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 348,463 shares of the biotechnology company's stock, valued at approximately $9,586,000. AEGOMarch 17, 2024 | marketbeat.comWellington Management Group LLP Has $157.83 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)Wellington Management Group LLP cut its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,067,864 shares of the biotechnology companyMarch 16, 2024 | finance.yahoo.comVCYT Apr 2024 30.000 callMarch 10, 2024 | marketbeat.comNorthern Trust Corp Raises Position in Veracyte, Inc. (NASDAQ:VCYT)Northern Trust Corp lifted its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 38.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 982,328 shares of the biotechnology company's stock after buying an additionMarch 8, 2024 | marketbeat.comQube Research & Technologies Ltd Has $3.72 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)Qube Research & Technologies Ltd raised its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 55.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,732 shares oMarch 7, 2024 | marketbeat.comInvesco Ltd. Grows Stock Position in Veracyte, Inc. (NASDAQ:VCYT)Invesco Ltd. lifted its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 38.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 476,349 shares of the biotechnology company's stock after buying an additioMarch 2, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Trexquant Investment LPTrexquant Investment LP boosted its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 87.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,161 shares of the biotechnology company's stock after buying anMarch 1, 2024 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Veracyte, Inc. (NASDAQ:VCYT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given aFebruary 29, 2024 | marketbeat.comDark Forest Capital Management LP Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)Dark Forest Capital Management LP bought a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,677 shares of the biotechnology company'sFebruary 27, 2024 | businesswire.comVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesFebruary 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | marketbeat.comMorgan Stanley Trims Veracyte (NASDAQ:VCYT) Target Price to $21.00Morgan Stanley cut their target price on shares of Veracyte from $22.00 to $21.00 and set an "underweight" rating on the stock in a research report on Monday.February 26, 2024 | markets.businessinsider.comVeracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst Outlook Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address WATCH: The Truth About Inflation (Ad)The full story on inflation is being CENSORED by the powers that be. But I have the REAL monthly numbers. And they are going to anger you. (Especially if you have money sitting in a 401k or IRA.) WATCH: The Truth About Inflation VCYT Media Mentions By Week VCYT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VCYT News Sentiment▼0.770.54▲Average Medical News Sentiment VCYT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VCYT Articles This Week▼103▲VCYT Articles Average Week Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Viridian Therapeutics News Today Guardant Health News Today Castle Biosciences News Today Fulgent Genetics News Today CareDx News Today Celcuity News Today Genetron News Today Burning Rock Biotech News Today Personalis News Today Fortrea News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VCYT) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
